Autonomix Medical (NASDAQ:AMIX – Get Free Report) and Profound Medical (NASDAQ:PROF – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.
Analyst Ratings
This is a breakdown of current recommendations for Autonomix Medical and Profound Medical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Autonomix Medical | 0 | 0 | 1 | 0 | 3.00 |
| Profound Medical | 0 | 0 | 2 | 1 | 3.33 |
Autonomix Medical presently has a consensus target price of $28.00, indicating a potential upside of 867.18%. Profound Medical has a consensus target price of $14.25, indicating a potential upside of 109.87%. Given Autonomix Medical’s higher probable upside, analysts plainly believe Autonomix Medical is more favorable than Profound Medical.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Autonomix Medical | N/A | N/A | -$15.43 million | ($16.07) | -0.18 |
| Profound Medical | $7.20 million | 28.33 | -$28.57 million | ($1.34) | -5.07 |
Autonomix Medical has higher earnings, but lower revenue than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
10.8% of Autonomix Medical shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 32.4% of Autonomix Medical shares are held by company insiders. Comparatively, 1.5% of Profound Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Autonomix Medical and Profound Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Autonomix Medical | N/A | -542.11% | -236.92% |
| Profound Medical | -349.41% | -85.22% | -64.87% |
Summary
Profound Medical beats Autonomix Medical on 8 of the 13 factors compared between the two stocks.
About Autonomix Medical
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
About Profound Medical
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
